Therapeutics: Cytochrome P450 3A5 (CYP3A5)

Cancer

INDICATION: Pancreatic cancer

Patient sample and mouse studies suggest inhibiting CYP3A5 could help treat drug-resistant pancreatic ductal adenocarcinoma (PDAC). In patient-derived PDAC cell lines, high expression of

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE